Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37


Antiretroviral Therapy and Pregnancy Outcomes in Developing Countries: A Systematic Review.

Alemu FM, Yalew AW, Fantahun M, Ashu EE.

Int J MCH AIDS. 2015;3(1):31-43. Review.


Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges.

Zash RM, Williams PL, Sibiude J, Lyall H, Kakkar F.

Expert Opin Drug Saf. 2016 Nov;15(11):1501-1513.


Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.

Papp E, Balogun K, Banko N, Mohammadi H, Loutfy M, Yudin MH, Shah R, MacGillivray J, Murphy KE, Walmsley SL, Silverman M, Serghides L.

J Infect Dis. 2016 May 15;213(10):1532-40. doi: 10.1093/infdis/jiw004. Epub 2016 Jan 5.


The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children.

Vreeman RC, Scanlon ML, McHenry MS, Nyandiko WM.

J Int AIDS Soc. 2015 Dec 2;18(Suppl 6):20258. doi: 10.7448/IAS.18.7.20258. eCollection 2015.


Association between maternal HIV infection and low birth weight and prematurity: a meta-analysis of cohort studies.

Xiao PL, Zhou YB, Chen Y, Yang MX, Song XX, Shi Y, Jiang QW.

BMC Pregnancy Childbirth. 2015 Oct 8;15:246. doi: 10.1186/s12884-015-0684-z. Review.


Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana.

Zash R, Souda S, Chen JY, Binda K, Dryden-Peterson S, Lockman S, Mmalane M, Makhema J, Essex M, Shapiro R.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):428-36. doi: 10.1097/QAI.0000000000000847.


Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?

Kakkar F, Boucoiran I, Lamarre V, Ducruet T, Amre D, Soudeyns H, Lapointe N, Boucher M.

J Int AIDS Soc. 2015 Jun 5;18:19933. doi: 10.7448/IAS.18.1.19933. eCollection 2015.


HIV-free survival according to the early infant-feeding practices; a retrospective study in an anti-retroviral therapy programme in Makurdi, Nigeria.

Anígilájé EA, Dabit OJ, Olutola A, Ageda B, Aderibigbe SA.

BMC Infect Dis. 2015 Mar 18;15:132. doi: 10.1186/s12879-015-0871-6.


Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir.

Samuel M, Bradshaw D, Perry M, Chan SY, Dhairyawan R, Byrne L, Smith K, Zhou J, Short CE, Naftalin C, Offodile N, Mandalia S, Roedling S, Shah R, Brook G, Poulton M, Rodgers M, Sarner L, Noble H, Hay P, Anderson J, Natha M, Hawkins D, Taylor G, de Ruiter A.

Infect Dis Obstet Gynecol. 2014;2014:961375. doi: 10.1155/2014/961375. Epub 2014 Sep 25.


Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.

Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Clark TD, Achan J, Ruel T, Nzarubara B, Kamya MR, Havlir DV, Cohan D.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):128-35. doi: 10.1097/QAI.0000000000000281.


HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction.

Papp E, Mohammadi H, Loutfy MR, Yudin MH, Murphy KE, Walmsley SL, Shah R, MacGillivray J, Silverman M, Serghides L.

J Infect Dis. 2015 Jan 1;211(1):10-8. doi: 10.1093/infdis/jiu393. Epub 2014 Jul 16.


Risk factors of HIV-1 vertical transmission (VT) and the influence of antiretroviral therapy (ART) in pregnancy outcome.

Barral MF, de Oliveira GR, Lobato RC, Mendoza-Sassi RA, Martínez AM, Gonçalves CV.

Rev Inst Med Trop Sao Paulo. 2014 Mar-Apr;56(2):133-8. doi: 10.1590/S0036-46652014000200008.


Correlates and outcomes of preterm birth, low birth weight, and small for gestational age in HIV-exposed uninfected infants.

Slyker JA, Patterson J, Ambler G, Richardson BA, Maleche-Obimbo E, Bosire R, Mbori-Ngacha D, Farquhar C, John-Stewart G.

BMC Pregnancy Childbirth. 2014 Jan 8;14:7. doi: 10.1186/1471-2393-14-7.


Safety of protease inhibitors in HIV-infected pregnant women.

Chougrani I, Luton D, Matheron S, Mandelbrot L, Azria E.

HIV AIDS (Auckl). 2013 Sep 27;5:253-62. doi: 10.2147/HIV.S33058. eCollection 2013. Review.


Influence of infection during pregnancy on fetal development.

Adams Waldorf KM, McAdams RM.

Reproduction. 2013 Oct 1;146(5):R151-62. doi: 10.1530/REP-13-0232. Print 2013. Review.


Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025.

Read JS, Huo Y, Patel K, Mitchell M, Scott GB.

J Pediatric Infect Dis Soc. 2012 Jun;1(2):92-102. doi: 10.1093/jpids/pis036. Epub 2012 May 3.


Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy.

Taylor AW, Mosimaneotsile B, Mathebula U, Mathoma A, Moathlodi R, Theebetsile I, Samandari T.

Infect Dis Obstet Gynecol. 2013;2013:195637. doi: 10.1155/2013/195637. Epub 2013 Mar 7.


Combination antiretroviral use and preterm birth.

Watts DH, Williams PL, Kacanek D, Griner R, Rich K, Hazra R, Mofenson LM, Mendez HA; Pediatric HIV/AIDS Cohort Study.

J Infect Dis. 2013 Feb 15;207(4):612-21. doi: 10.1093/infdis/jis728. Epub 2012 Nov 29.


Preconception and contraceptive care for women living with HIV.

Hoyt MJ, Storm DS, Aaron E, Anderson J.

Infect Dis Obstet Gynecol. 2012;2012:604183. doi: 10.1155/2012/604183. Epub 2012 Oct 11. Review.

Items per page

Supplemental Content

Support Center